๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacogenomic approaches in Alzheimer's disease drug development

โœ Scribed by Jeroen Aerssens

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
79 KB
Volume
56
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Role of pharmacogenomics in drug develop
Role of pharmacogenomics in drug development
โœ Hakon Hakonarsson; Kari Stefansson ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 105 KB ๐Ÿ‘ 1 views
Drug treatment of alzheimer's disease
Drug treatment of alzheimer's disease
โœ Leon J. Thal ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB

## Drug Treatment of Alzheimer's Disease A number of discoveries have occurred in the last decade that have enhanced the quest for a drug treatment for dementia. These include-1. the realization that memory loss is not an inevitable consequence of aging; 2. the discovery that the pathologies of Al

Cholinergic abnormalities in Alzheimer's
Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?
โœ Lisa R. Fodero; David H. Small ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB ๐Ÿ‘ 1 views

## Abstract Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and behavioral changes. Cholinesterase inhibitors are currently the drugs of choice for the treatment of AD. However, alternatives to cholinesterase inhibitors such as muscarinic and nicotinic